Everolimus exhibits efficacy as a radiosensitizer in a model of non-small cell lung cancer
| Autor: | Thomas E. Darga, Everett E. Vokes, Masha Kocherginsky, Ralph R. Weichselbaum, Helena J. Mauceri, Harold G. Sutton, Joel Kochanski |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Cancer Research
Radiosensitizer Radiation-Sensitizing Agents Lung Neoplasms medicine.medical_treatment Gene Expression Mice Nude Pharmacology Mice Carcinoma Non-Small-Cell Lung Cell Line Tumor Radiation Ionizing medicine Animals Humans Everolimus Phosphorylation Lung cancer PI3K/AKT/mTOR pathway Cisplatin Sirolimus Chemotherapy Oncogene business.industry Cancer Ribosomal Protein S6 Kinases 70-kDa General Medicine medicine.disease Combined Modality Therapy Xenograft Model Antitumor Assays Oncology Female business medicine.drug |
| Zdroj: | Oncology reports. 27(5) |
| ISSN: | 1791-2431 |
| Popis: | Signaling pathways that activate mTOR (mammalian target of rapamycin) are altered in many human cancers and these alterations are associated with prognosis and treatment response. mTOR inhibition can restore sensitivity to DNA damaging agents such as cisplatin. The rapamycin derivative everolimus exhibits antitumor activity and is approved for patients with renal cell cancer. Clinically, everolimus has also been evaluated in patients with advanced non-small cell lung cancer (NSCLC) that were refractory to chemotherapy and epidermal growth factor receptor tyrosine kinase inhibitors. We tested the effects of combined treatment with everolimus (RAD001) and fractionated radiation using a xenograft model of human NSCLC (A549 cells). In growth studies, mean tumor volume was reduced in the everolimus plus 30 Gy cohort with significant tumor growth suppression compared to 30 Gy alone (p=0015), or everolimus alone (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|